We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
CALL
Goldman Sachs
GS
$313B
| $17.4M | 0.04% |
50,600
-4,300
| -8% | -$1.5M |
|
502
Kraft Heinz
KHC
$30.4B
| $17.3M | 0.04% |
425,394
+388,160
| +1,042% | +$14.7M |
|
503
CALL
Moderna
MRNA
$21.5B
| $17.3M | 0.04% |
96,200
+29,000
| +43% | +$4.74M |
|
504
Teleflex
TFX
$5.85B
| $17.3M | 0.04% |
69,171
+27,909
| +68% | +$6.16M |
|
505
Quest Diagnostics
DGX
$25.1B
| $17.2M | 0.04% |
110,222
+86,337
| +361% | +$12.4M |
|
506
Owens Corning
OC
$11.5B
| $17.2M | 0.04% |
202,085
+90,831
| +82% | +$7.96M |
|
507
Brookfield
BN
$102B
| $17.2M | 0.04% |
820,956
+696,502
| +560% | +$15.6M |
|
508
Cogent Biosciences
COGT
$6.79B
| $17.1M | 0.04% |
+1,480,658
| New | +$18.3M |
|
|
PTOC
509
DELISTED
Pine Technology Acquisition Corp. Class A Common Stock
PTOC
| $17.1M | 0.04% |
1,688,385
| – | – |
|
510
Liberty Broadband Class C
LBRDK
$4.15B
| $17M | 0.04% |
+223,411
| New | +$18.2M |
|
511
iShares 3-7 Year Treasury Bond ETF
IEI
$18.1B
| $17M | 0.04% |
+148,300
| New | +$17M |
|
512
WEC Energy
WEC
$37.7B
| $17M | 0.04% |
181,585
+111,221
| +158% | +$10.3M |
|
|
ACAH
513
DELISTED
Atlantic Coastal Acquisition Corp. Class A Common Stock
ACAH
| $17M | 0.04% |
1,697,110
| – | – |
|
|
EGLE
514
DELISTED
Eagle Bulk Shipping Inc.
EGLE
| $17M | 0.04% |
340,189
+30,251
| +10% | +$1.52M |
|
|
GSQD
515
DELISTED
G Squared Ascend I Inc.
GSQD
| $16.9M | 0.04% |
1,674,585
| – | – |
|
516
Autohome
ATHM
$2.43B
| $16.9M | 0.04% |
+551,499
| New | +$16.4M |
|
517
Caesars Entertainment
CZR
$6.1B
| $16.9M | 0.04% |
405,591
+252,353
| +165% | +$11.2M |
|
518
CALL
Blackrock
BLK
$164B
| $16.9M | 0.04% |
+23,800
| New | +$15.9M |
|
|
ROSS
519
DELISTED
Ross Acquisition Corp II
ROSS
| $16.9M | 0.04% |
1,665,604
| – | – |
|
520
PUT
Oracle
ORCL
$331B
| $16.8M | 0.04% |
206,100
-159,500
| -44% | -$12.1M |
|
521
SunPower Inc
SPWR
$81.7M
| $16.8M | 0.04% |
1,664,828
| – | – |
|
522
PUT
iShares Semiconductor ETF
SOXX
$44.2B
| $16.8M | 0.04% |
144,900
+96,000
| +196% | +$11.1M |
|
523
Sea Limited
SE
$61.2B
| $16.7M | 0.04% |
321,829
+76,011
| +31% | +$4.1M |
|
|
SILK
524
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $16.7M | 0.04% |
316,653
+273,014
| +626% | +$13.3M |
|
525
Johnson Controls International
JCI
$87.5B
| $16.7M | 0.04% |
+261,095
| New | +$16M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.